Xinkanghe Biopharmaceutical

Xinkanghe Biopharmaceutical is a clinical-stage biotechnology company based in Beijing, China, focused on developing innovative small molecule and biologic therapies for autoimmune and inflammatory diseases. The company utilizes a proprietary drug discovery platform to target key immunological pathways, including RORγt and TYK2. Its lead program, XKH001, is a highly selective RORγt inverse agonist currently in Phase 2 clinical development for plaque psoriasis. Xinkanghe's pipeline also includes a TYK2 inhibitor and an IL-17A monoclonal antibody, aiming to provide next-generation treatments for conditions such as atopic dermatitis and ankylosing spondylitis. The company is backed by prominent venture capital firms and aims to address significant unmet medical needs in the global immunology market.